Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?

Core Viewpoint - Eli Lilly's stock performance is significantly influenced by its weight loss drugs, Zepbound and Mounjaro, which have driven substantial revenue growth and share price appreciation, leading to speculation about a potential stock split in the future [2][8][11]. Company Performance - Eli Lilly's stock has increased approximately 160% since the approval of Mounjaro, currently trading over $700 per share, with a peak of around$960 in September [3][4]. - The company has reported double-digit revenue growth in recent quarters, largely attributed to the popularity of its weight loss portfolio [8]. Stock Split Speculation - Investors are curious if Eli Lilly will initiate a stock split, especially given its historical openness to such actions, having completed four in the past, the last being in 1997 [9]. - The recent decline in Lilly's share price may prompt management to consider a stock split to attract more investors and highlight the ongoing potential of its weight loss drugs [11]. Market Context - The obesity drug market is projected to reach $130 billion by the end of the decade, positioning Eli Lilly favorably alongside competitors like Novo Nordisk [13]. - Despite trading near record highs, Lilly's stock price is significantly higher than its peers, which may deter some investors [15].